Navigation

NICE Scientific Advice

NICE-TOPRA 2-day Workshop on Health Technology Assessment

19-20 March 2014

An essential introduction to HTA for regulatory professionals who are starting to get involved in HTA as part of product development plans.

Register

National Parallel Scientific Advice

NICE and MHRA re-launch a parallel advice service for developers of medicinal products with an option to request an advisory input from CPRD.

Learn more

Pharmaceutical products

Scientific advice pills imageProduct specific NICE advice (standard process)

Product specific NICE advice alongside the regulators

Find out what advice can be requested

Devices and diagnostics

Scientific advice stethoscopeWe are developing new services targeted to the manufacturers of medical technologies (devices & diagnostics).

Contact us to discuss the most appropriate option for your product.

About NICE Scientific advice

NICE Scientific Advice (SA) provides fee-for-service consultation to pharmaceutical companies. By reviewing early product development plans we can advise companies on whether these will generate relevant evidence for future submissions to NICE.

Based on a briefing book, written questions submitted by the company and a face-to-face meeting, NICE SA provides an advice report. There is a fee for this service.

More recently NICE SA has expanded the range of services we offer to give advice alongside regulators.

More about us

Why seek advice?

NICE evaluation programmes require certain types of evidence about the technology being appraised. A company may wish to seek advice from NICE to ensure that their proposed development plans can produce evidence that is relevant for a future NICE evaluation.

When can advice be sought?

Advice can be sought at any time. However, a useful time for requesting scientific advice could be during phase II studies before the planning of phase III studies. The earlier in the development process the less specific the advice can be, and the later in the process the less likely it is that companies will be able to make changes to the design of clinical trials.

This page was last updated: 06 January 2014

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.